Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.

Minimal residual disease (MRD) is a powerful determinant of overall outcome in multiple myeloma (MM). Previous studies have demonstrated that the presence of MRD at the traditional day 100 assessment point following autologous stem cell transplant (ASCT) independently predicts for both progression-